Skip to content

    VERTEX PHARMACEUTICALS INC / MA

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Trend
    EarningsRevenue
    $2.65B
    $2.77B
    $2.91B
    $2.77B
    $2.96B
    +12.1%
    $3.08B
    +11.0%
    $3.19B
    +9.5%
    $2.99B
    +7.8%
    Strengthening
    Operating Profit
    -$3.51B
    $1.12B
    $1.03B
    $630.10M
    $1.15B
    $1.19B
    +6.3%
    $1.21B
    +17.5%
    $1.14B
    +80.6%
    Strengthening
    Net Profit
    -$3.59B
    $1.05B
    $913.00M
    $646.30M
    $1.03B
    $1.08B
    +3.6%
    $1.19B
    +30.5%
    $1.03B
    +59.6%
    Strengthening
    EPS
    $-13.92
    $4.05
    $2.52
    $4.02
    $4.24
    +4.7%
    $4.06
    +61.1%
    Strengthening
    Other Income
    Interest
    $9.90M
    $7.50M
    $2.80M
    $3.00M
    $3.70M
    -62.6%
    $3.30M
    -56.0%
    $3.30M
    +17.9%
    Weakening
    Depreciation
    Profit before Tax
    -$3.39B
    $1.22B
    $1.14B
    $730.40M
    $1.28B
    $1.30B
    +6.1%
    $1.33B
    +17.1%
    $1.25B
    +71.5%
    Strengthening
    MarginsOPM
    -132.8%
    40.3%
    35.2%
    22.8%
    38.8%
    38.6%
    -4.2%
    37.8%
    +7.3%
    38.1%
    +67.5%
    Strengthening
    Tax
    -6.0%
    14.6%
    19.7%
    11.5%
    19.5%
    16.6%
    +13.8%
    10.5%
    -46.6%
    17.7%
    +53.6%
    Strengthening
    ReturnsROIC
    -28.0%
    8.1%
    7.1%
    5.0%
    8.0%
    8.4%
    +3.6%
    9.3%
    +30.5%
    8.0%
    +59.6%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$2.65B$3.11B$5.99B$6.79B$10.50B$10.37B$4.57B$5.08B$5.49B
    Short-Term Investments$518.11M$698.97M$670.70M$729.90M$274.50M$849.20M$1.55B$1.52B$1.75B
    Total Current Assets$3.84B$4.82B$8.13B$9.56B$13.23B$14.14B$9.60B$11.20B$11.73B
    Net PP&E$812.00M$833.28M$1.28B$1.42B$1.46B$1.45B$2.58B$3.08B$3.29B
    Goodwill$50.38M$1.00B$1.00B$1.00B$1.09B$1.09B$1.09B$1.09B$1.09B
    Intangibles$0$400.00M$400.00M$400.00M$603.60M$839.90M$825.90M$424.20M$418.50M
    Total Assets$6.25B$8.32B$11.75B$13.43B$18.15B$22.73B$22.53B$25.64B$26.48B
    LiabilitiesTotal Current Liabilities$1.12B$1.33B$1.88B$2.14B$2.74B$3.55B$3.56B$3.86B$3.88B
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$84.29M$350.50M$377.40M$379.50M$348.60M$1.54B$1.85B$1.99B
    Total Liabilities$1.81B$2.23B$3.06B$3.33B$4.24B$5.15B$6.12B$6.98B$7.12B
    EquityCommon Stock & APIC$2.55M$2.59M$2.60M$2.50M$2.60M$2.60M$2.60M$2.50M$2.50M
    Retained Earnings-$2.99B-$1.85B$858.70M$3.20B$6.52B$10.14B$9.61B$13.56B$14.59B
    Total Equity$4.44B$6.09B$8.69B$10.10B$13.91B$17.58B$16.41B$18.67B$19.36B
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$1.27B$1.57B$3.25B$2.64B$4.13B$3.54B-$492.60M$3.63B$4.24B
    Cash from Investing-$202.16M-$1.24B$99.40M-$340.90M-$321.10M-$3.14B-$3.77B-$945.40M-$1.32B
    Cash from Financing-$71.22M$126.80M-$505.30M-$1.48B-$67.70M-$562.20M-$1.49B-$2.26B-$2.12B
    SummaryCapital Expenditure-$95.45M-$75.40M-$259.80M-$235.00M-$204.70M-$200.40M-$297.70M-$437.60M-$530.30M
    Free Cash Flow$1.17B$1.49B$2.99B$2.41B$3.93B$3.34B-$790.30M$3.19B$3.71B
    FCF Margin38.5%35.9%48.2%31.8%44.0%33.8%-7.2%26.6%30.4%